WallStreetZenWallStreetZen

NASDAQ: CTOR
Citius Oncology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CTOR stock forecasts and price targets.

Forecast return on equity

Is CTOR forecast to generate an efficient return?

Company
137.14%
Industry
6.81%
Market
145.94%
CTOR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CTOR forecast to generate an efficient return on assets?

Company
48.03%
Industry
16.49%
CTOR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CTOR earnings per share forecast

What is CTOR's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.61
Avg 2 year Forecast
$0.11
Avg 3 year Forecast
$0.52

CTOR revenue forecast

What is CTOR's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$21.2M+278.51%
Avg 2 year Forecast
$97.1M+1,629.67%
Avg 3 year Forecast
$160.6M+2,761.31%
CTOR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CTOR revenue growth forecast

How is CTOR forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
307%
Industry
11.83%
Market
16.81%
CTOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CTOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CTOR vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
CTOR$0.65N/AN/A
INCR$1.10N/AN/A
TLPH$1.03$3.00+191.26%Strong Buy
IXHL$3.76$18.00+378.72%Strong Buy
SCYX$4.07N/AN/A
View Top Pharmaceutical Stocks

Citius Oncology Stock Forecast FAQ

What is CTOR's earnings growth forecast for 2026-2028?

(NASDAQ: CTOR) Citius Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 15.06%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.28%.

Citius Oncology's earnings in 2026 is -$42,510,376.On average, 3 Wall Street analysts forecast CTOR's earnings for 2026 to be -$56,904,497, with the lowest CTOR earnings forecast at -$54,672,948, and the highest CTOR earnings forecast at -$58,578,159. On average, 3 Wall Street analysts forecast CTOR's earnings for 2027 to be $10,432,491, with the lowest CTOR earnings forecast at $10,023,374, and the highest CTOR earnings forecast at $10,739,329.

In 2028, CTOR is forecast to generate $48,368,822 in earnings, with the lowest earnings forecast at $46,472,006 and the highest earnings forecast at $49,791,435.

If you're new to stock investing, here's how to buy Citius Oncology stock.

What is CTOR's revenue growth forecast for 2026-2028?

(NASDAQ: CTOR) Citius Oncology's forecast annual revenue growth rate of 307% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 11.83%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.81%.

Citius Oncology's revenue in 2026 is $5,611,409.On average, 3 Wall Street analysts forecast CTOR's revenue for 2026 to be $1,974,920,773, with the lowest CTOR revenue forecast at $1,897,560,411, and the highest CTOR revenue forecast at $2,033,034,025. On average, 3 Wall Street analysts forecast CTOR's revenue for 2027 to be $9,024,662,679, with the lowest CTOR revenue forecast at $8,670,776,217, and the highest CTOR revenue forecast at $9,290,124,016.

In 2028, CTOR is forecast to generate $14,929,062,114 in revenue, with the lowest revenue forecast at $14,343,280,529 and the highest revenue forecast at $15,367,933,397.

What is CTOR's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: CTOR) forecast ROA is 48.03%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 16.49%.

What is CTOR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CTOR) Citius Oncology's current Earnings Per Share (EPS) is -$0.47. On average, analysts forecast that CTOR's EPS will be -$0.61 for 2026, with the lowest EPS forecast at -$0.59, and the highest EPS forecast at -$0.63. On average, analysts forecast that CTOR's EPS will be $0.11 for 2027, with the lowest EPS forecast at $0.11, and the highest EPS forecast at $0.12. In 2028, CTOR's EPS is forecast to hit $0.52 (min: $0.50, max: $0.54).

What is CTOR's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: CTOR) forecast ROE is 137.14%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.